RPG Life Sciences Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹212 Cr +16.5% YoYSee revenue, profit and what management said. You are viewing Q2 FY25.
RL

RPG Life Sciences Ltd

Q2 FY25Pharmaceuticals & Biotechnology

RPG Life Sciences Q2 FY25 earnings call: Revenue & Margins

Q2 FY25 investor presentation: what the company reported on revenue, margins and capex.

Based on RPG Life Sciences Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹2,900
Market cap₹4.6K Cr
P/E39.7

The short version

Revenue from Operations:. Q2 FY25 EBITDA: Rs. 47.9 Cr with a margin of 31.5%, up from Rs. 39.1 Cr and 25.5% margin in Q2 FY24.

From RPG Life Sciences Ltd's Q2 FY25 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Revenue from Operations:
  • Q2 FY25: ₹172.2 Crores
  • Q2 FY24: ₹153.6 Crores
  • YoY Growth: +12.1%
  • Sales Growth by Segments (H1 FY25 vs H1 FY24):
  • Domestic Formulations (66% of sales): 10% growth
  • API (15% of sales): 14% growth
  • International Formulations (19% of sales): 16% growth
  • Outlook:
  • Focus on scaling up business through comprehensive 7 pillars including innovation, capacity expansion, and talent acquisition (Page 43).

2 more points from RPG Life Sciences Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what RPG Life Sciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Capex infusion of ~₹140 crore aimed at expanding global play (Page 12).
  • Modernization and capacity expansion of formulations and API plants highlighted as part of business growth strategy (Page 42).
  • State-of-the-art, modern, cost-efficient cGMP compliant plants approved by EU/PICS/TGA with ~2X higher capacity targeted for niche-focused R&D pipeline (Page 43).
  • Plant modernization and capacity expansion are ongoing transformation projects (Page 11).

2 more points from RPG Life Sciences Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what RPG Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what RPG Life Sciences Ltd said on order book & pipeline — free account, 30 seconds.

RPG Life Sciences Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹212 Cr, net profit ₹28 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q2 FY25)

    Q2’FY25 total income grew 5% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

  • Wockhardt (Q2 FY25)

    Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Key concall takeaways from Wockhardt Ltd's Q2 FY25…

  • Anuh Pharma (Q2 FY25)

    Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) . Key concall takeaways from Anuh Pharma Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

  • Themis Medicare (Q2 FY25)

    117.01 Cr, up 11.67% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

RPG Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were RPG Life Sciences Ltd Q2 FY25 results?

Revenue from Operations:. Q2 FY25 EBITDA: Rs. 47.9 Cr with a margin of 31.5%, up from Rs. 39.1 Cr and 25.5% margin in Q2 FY24.

What is RPG Life Sciences Ltd share price analysis?

RPG Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 39.7 with a market cap of ₹4,635 Cr. Investors should review the full earnings analysis for detailed insights.

Is RPG Life Sciences Ltd planning capital expenditure?

Capex infusion of ~₹140 crore aimed at expanding global play (Page 12).

Keep RPG Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.